Session 4: Managing Dysgeusia, Neuropathy and Other Toxicities with Bispecific Antibodies in Multiple Myeloma

Experts on multiple myeloma present the case of a 61-year-old with relapsed/refractory multiple myeloma (MM) treated with a BCMA bispecific antibody who develops dysgeusia and offer their initial impressions.

An expert panel discusses the management of dysgeusia associated with bispecific antibodies in treating patients with multiple myeloma.

A panel of experts on multiple myeloma offer insights on the case of a 57-year-old with relapsed/refractory MM treated with an FcRH5 bispecific antibody who develops peripheral neuropathy.

A comprehensive discussion on managing neurotoxicity associated with bispecific antibodies in multiple myeloma.

Michael Scordo, MD, gives an overview of a study on dysgeusia seen in patients with multiple myeloma following autologous stem cell transplant or treatment with novel agents.

An expert panel discusses the case of a 49-year-old with relapsed/refractory multiple myeloma treated with a BCMA bispecific antibody who develops adenoviral infection.

A panel of experts on multiple myeloma discuss the use of IVIG in the management of hypogammaglobulinemia in patients treated with bispecific antibodies.

An expert panel offers their initial impressions on the case of a 77-year-old with multiple myeloma treated with a BCMA bispecific antibody who develops neutropenia.

Experts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.

Saad. Z. Usmani, MD, leads a panel of experts in discussing toxicities associated with treatment for multiple myeloma.